Trials / Recruiting
RecruitingNCT07439796
A Study of ORN252 in Healthy Participants
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORN252 in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Orna Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ORN252 | ORN252 is a lipid nanoparticle encapsulating a circular RNA encoding an anti-CD19 CAR protein. |
Timeline
- Start date
- 2026-03-16
- Primary completion
- 2026-12-01
- Completion
- 2027-03-01
- First posted
- 2026-02-27
- Last updated
- 2026-04-16
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT07439796. Inclusion in this directory is not an endorsement.